In vitro antimicrobial activity of cefsulodin and kanamycin in combinations

Soumendra Nath Maity, Mallikarjuna Reddy Chintaparthi, Hima Bindu M, R. C. Kanta, Indu Kapur


Background:Infectious diseases are the greatest challenge of the world. The main failure in the treatment of infectious diseases is development of antibiotic resistance by the infective agents. Combination drug therapy is proposed to be more successful to contain diseases. But before the selection of combination of antibiotics, it is important to determine interaction of such antibiotics. Two antibiotics may have either synergistic or antagonistic action. In this study it was designed to find out the Minimum Inhibitory Concentration (MIC), and Minimum Bactericidal Concentration (MBC), which is usually used for the quantitative assessment of bacterial sensitivity to antibiotics.

Methods:Checkerboard titration in microtitre trays used for this assay, and Fractional Inhibitory Concentration (FIC) and Fractional Bactericidal Concentration (FBC) measured to identify the type of interaction between the two antibiotics. Cefsulodin (Cef) and Kanamycin (Kan) were used against Escherechia coli (Esch. coli) and Staphylococcus aureus (Staph. aureus) to determine the efficacy of these antibiotics in combination.

Results:MIC of cefsulodin and kanamycin against Staph. aureus was 3.125 and 3.125 respectively. MIC of Cef for Esch. coli was 6.25 and for Kan 50. FIC for Staph. aureus was 1. FIC for Esch. coli was different in different antibiotic concentrations and the least value was 0.37. There was no bactericidal effect of these antibiotics in combination against these organisms.

Conclusion:Combination of two drugs cefsulodin and kanamycin showed synergistic action against Esch. coli and additive against Staph. aureus. So combined drug therapy can be used for better treatment with low toxicity, broad spectrum activity, and prevent emergence of drug resistance organism.



Combination drug therapy, Cefsulodin, Kanamycin, Staph. aureus, Esch. coli

Full Text:



Vito R. Iacoviello, Stephen H. Zinner. Principles of anti-infective therapy. In: Jonathan Cohen, William G. Powderly, eds. Mosby Infectious Diseases. 2nd ed. Spain: Elsevier Limited; 2004: 1705-1715.

Philip S. Brachman. Infectious diseases-past, present, and future. Int J Epidemiol. 2003;8:684-6.

Franz-Josef Schmitz, Ad C. Fluit. Mechanisms of antibacterial resistance. In: Jonathan Cohen, William G. Powderly, eds. Mosby Infectious Diseases. 2nd ed. Spain: Elsevier Limited; 2004: 1733-1748.

JL Avorn, JF Barrett, PG Davey, SA McEwen, TF O’Brien, SB Levy. Antibiotic resistance: synthesis of recommendations by expert policy groups. In: WHO and Allience for the Prudent Use of Antibiotics. Boston, MA, United States of America: WHO; 2000: 1-155.

Harry W. Lampiris, Daniel S. Maddix. Clinical use of antimicrobial agents. In: Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor, eds. Lange Basic & Clinical Pharmacology. 12th ed. New Delhi, ND: Tata McGraw-Hill; 2012: 901-913.

Lorenzo Drago, Elena De Vecchi, Lucia Nicola, Maria Rita Gismondo. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect Dis. 2007;7:111.

Stuart B. Levy. Factors impacting on the problem of problem of antibiotic resistance. J Antimicrob Chemother. 2002;49:25-30.

Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;4:71-8.

Ting-Chao Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. Am Associ Cancer Res. 2010;70:440-6.

Graeme N. Forrest, Kimberly Tamura. Rifampin combination therapy for non-mycobaterial infections. Clin Microbiol Rev. 2010;23(1):14-34.

Ellsworth M. Campbell and Lin Chao. A population model evaluating the consequences of the evolution of double-resistance and tradeoffs on the benefits of two-drug antibiotic treatments. PLos One. 2014;9(1):e86971.

Peter Torella Joseph, Chait Remy, Kishony Roy. Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol. 2010;6(6):e1000796.

Sharom JR, Bellows DS, Tyers M. From large networks to small molecules. Curr Opin Chem Biol. 2004;8:81-90.

Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Drug Discov. 2005;4:71-8.

H. Hsieh Michael, M. Yu Chen, L. Yu Victor, W. Chow Joseph. Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis. 1993;16:343-9.

ASM Science. synergism testing: broth microdilution checkerboard and broth macrodilution methods, 2012. Available at: 000000000260/05.12.pdf. Accessed 12 May 2012.

Saito M, Azuma K, Nishino T, Tanino T. Combination action of sisomicin, dibekacin and cefotetan, cefotaxime, latamoxef, and cefsulodin against Escherichia coli, Serratia marcescens, and Pseudomonas aeruginosa. Jpn J Antibiot. 1983;36(10):2833-43.

AL Baltch, C Bassey, G Fanciullo, RP Smith. In vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus. J Antimicrob Chemother. 1987;19(1):45-8.